RxDoctor Payments Data

Thomas Vonderfecht, MD

Family Medicine · Grand Island, NENPI 1750949707

Payments from drug & device makers

$1,590in general payments, 2019–2025

Across 137 payments — averaging $11.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$804
  • Novo Nordisk$134
  • Otsuka America Pharmaceutical, Inc.$98
  • Abbott$97
  • Lilly USA, LLC$62
  • Johnson & Johnson$38
  • plus $356 from 14 others

What the payments were for

  • Food & beverage$1,590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,590 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$165,699
Medicare patients
378
Services billed
4,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$68,935
EliquisApixaban59$50,160
UbrelvyUbrogepant35$48,691
TrulicityDulaglutide29$45,505
XareltoRivaroxaban35$38,427
FarxigaDapagliflozin Propanediol43$34,642
MounjaroTirzepatide30$33,647
JardianceEmpagliflozin37$32,400
ArexvyRsvpref3 Antigen/As01e/Pf73$22,670
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$17,083
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$12,333
Tresiba Flextouch U-100Insulin Degludec12$9,522
EntrestoSacubitril/Valsartan12$8,990
ShingrixVaricella-Zoster Ge/As01b/Pf41$8,911
Tresiba Flextouch U-200Insulin Degludec11$6,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$62$79,15259 claims
Novo NordiskOzempic$134$68,93574 claims
AstraZenecaFarxiga, Breztri Aerosphere$38$51,72559 claims
AbbVieUbrelvy$804$48,69135 claims
Johnson & JohnsonXarelto$38$38,42735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →